GUT: Vitamin B12 may improve SVR rates in HCV infected patients...

Study posted 7/18/12 via the journal GUT.  Researchers in Italy find a link between 5000 ug every 4 weeks of vitamin B12 and improved SVR... especially in the more difficult-to-treat genotype 1 patients with high baseline viral loads.  Researchers noted a 34% improvement in SVR in the arms containing B12 than in the arms that didn't. That's pretty cool in my book, but let's do a gut check all the same. OK, it's a small study, it's European (which means the patients have a higher probability of being Caucasian, lower BMI, CC alelle, genotype 1b, all that stuff that makes these patients more likely to respond to traditional pegylated interferon + ribavirin therapy than patient types over here in the States) but hey!! Vitamin B12 can be had on the cheap! Further prospective and larger clinical trials will have to be done to confirm or deny the seemingly extra added boost to SVR rates, especially with the new standard of care. Let's hope it's not another silymarin experience.

GUT
Vitamin B12 supplements may help treat hepatitis C

Safe and inexpensive option for boosting response rate to antiviral drugs

[Vitamin B12 supplementation improves the rate of sustained viral response in patients chronically infected with hepatitis C virus Online First doi 10.1136/gutjnl-2012-302344]

Adding vitamin B12 to standard hepatitis C virus (HCV) treatment significantly boosts the body’s ability to keep the virus at bay, indicates a pilot study published online in the journal Gut.

The effects were particularly strong in patients whose infection was proving difficult to treat effectively, the findings showed.

Between 60% and 80% of those infected with the viral liver infection HCV will go on to develop chronic hepatitis, and roughly a third of them will progress to cirrhosis and terminal liver disease.

Standard treatment of interferon (peg IFN) and ribavarin clears the virus in about 50% of patients infected with genotype 1 HCV and 80% of those infected with genotypes 2 or 3.   But this approach fails to clear the virus in around half of all those infected with HCV or the infection returns once treatment stops.  

While trials of new generation antiviral drugs show promise, they are expensive, and can make treatment more difficult. And questions still remain about how well they will work in practice, say the authors.

Experimental research dating back a decade suggests that vitamin B12 may have a role in suppressing HCV. The liver is the body’s primary storage centre for vitamin B12, but this capacity is impaired by diseases directly affecting the organ. The researchers therefore wanted to see if adding vitamin B12 to standard treatment would make a difference.

Ninety four patients with HCV infection were randomly allocated to receive standard treatment or standard treatment plus vitamin B12 (5000 ug every 4 weeks) for between 24 (genotypes 2 and 3) and 48 weeks (genotype 1).

The body’s ability to clear the virus was assessed after 4 weeks (rapid viral response), after 12 weeks (complete early viral response), at the end of treatment and at 24 weeks after stopping treatment (sustained viral response).

There was no difference between the two treatment approaches at 4 weeks, but there were significant differences in response at all the other time points, particularly 24 weeks after stopping treatment, which is the aim of HCV treatment and the closest it can be get to a cure.  

The effects were also significantly greater among those who carried the type 1 strain, which is particularly hard to treat, and those high levels of infection (high viral load) to begin with.

Overall, adding vitamin B12 to standard therapy strengthened the rate of sustained viral response by 34%, the findings showed.

The authors conclude that until clear eligibility criteria for treatment with the new generation antiviral drugs are established, standard treatment plus vitamin B12 is a safe and inexpensive alternative, particularly for those who carry a strain of the virus that is hard to treat.

They add: “This strategy would be especially useful in those countries where, owing to limited economic means, the new generation antiviral therapies cannot be given in routine practice.”